Research ArticleOriginal Article
Open Access

Hyperlipidemia in rheumatoid arthritis patients in Saudi Arabia

Correlation with C-reactive protein levels and disease activity

Suzan M. Attar
Saudi Medical Journal June 2015, 36 (6) 685-691; DOI: https://doi.org/10.15537/smj.2015.6.10557

References

  1. ↵
    1. Al-Dalaan A,
    2. Al Ballaa S,
    3. Bahabri S,
    4. Biyari T,
    5. Al Sukait M,
    6. Mousa M
    (1998) The prevalence of rheumatoid arthritis in the Qassim region of Saudi Arabia. Ann Saudi Med 18:396–397.
    OpenUrlPubMed
  2. ↵
    1. del Rincón ID,
    2. Williams K,
    3. Stern MP,
    4. Freeman GL,
    5. Escalante A
    (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737–2745.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Snow MH,
    2. Mikuls TR
    (2005) Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. Curr Opin Rheumatol 17:234–241.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Bartels CM,
    2. Kind AJ,
    3. Thorpe CT,
    4. Everett CM,
    5. Cook RJ,
    6. McBride PE,
    7. et al.
    (2012) Lipid testing in patients with rheumatoid arthritis and key cardiovascular-related comorbidities: a medicare analysis. Semin Arthritis Rheum 42:9–16.
    OpenUrlCrossRefPubMed
    1. Peters MJ,
    2. Symmons DP,
    3. McCarey D,
    4. Dijkmans BA,
    5. Nicola P,
    6. Kvien TK,
    7. et al.
    (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325–331.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Park YB,
    2. Choi HK,
    3. Kim MY,
    4. Lee WK,
    5. Song J,
    6. Kim DK,
    7. et al.
    (2002) Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 113:188–193.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Choy E,
    2. Sattar N
    (2009) Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 68:460–469.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Myasoedova E,
    2. Crowson CS,
    3. Kremers HM,
    4. Roger VL,
    5. Fitz-Gibbon PD,
    6. Therneau TM,
    7. et al.
    (2011) Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 70:482–487.
    OpenUrlAbstract/FREE Full Text
    1. Maradit-Kremers H,
    2. Nicola PJ,
    3. Crowson CS,
    4. Ballman KV,
    5. Gabriel SE
    (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52:722–732.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Amaya-Amaya J,
    2. Sarmiento-Monroy JC,
    3. Mantilla RD,
    4. Pineda-Tamayo R,
    5. Rojas-Villarraga A,
    6. Anaya JM
    (2013) Novel risk factors for cardiovascular disease in rheumatoid arthritis. Immunol Res 56:267–286.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Amaya-Amaya J,
    2. Montoya-Sánchez L,
    3. Rojas-Villarraga A
    (2014) Cardiovascular involvement in autoimmune diseases. Biomed Res Int 2014, 367359.
  12. ↵
    1. Scott IC,
    2. Ibrahim F,
    3. Johnson D,
    4. Scott DL,
    5. Kingsley GH
    (2012) Current limitations in the management of cardiovascular risk in rheumatoid arthritis. Clin Exp Rheumatol 30:228–232.
    OpenUrlPubMed
  13. ↵
    1. del Rincón I,
    2. Escalante A
    (2003) Atherosclerotic cardiovascular disease in rheumatoid arthritis. Curr Rheumatol Rep 5:278–286.
    OpenUrlPubMed
  14. ↵
    1. Soubrier M,
    2. Zerkak D,
    3. Dougados M
    (2006) Indications for lowering LDL cholesterol in rheumatoid arthritis: an unrecognized problem. J Rheumatol 33:1766–1769.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Willerson JT,
    2. Ridker PM
    (2004) Inflammation as a cardiovascular risk factor. Circulation 109(21 Suppl 1):II2–II10.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Neogi T,
    2. Aletaha D,
    3. Silman AJ,
    4. Naden RL,
    5. Felson DT,
    6. Aggarwal R,
    7. et al.
    (2010) The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum 62:2582–2591.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    (2002) National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421.
    OpenUrlFREE Full Text
    1. Aletaha D,
    2. Ward MM,
    3. Machold KP,
    4. Nell VP,
    5. Stamm T,
    6. Smolen JS
    (2005) Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 52:2625–2636.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. McCarey DW,
    2. McInnes IB,
    3. Madhok R,
    4. Hampson R,
    5. Scherbakov O,
    6. Ford I,
    7. et al.
    (2004) Trial of Atorvastatin Rheumatoid Arthritis (TARA):double-blind, randomized placebo-controlled trial. Lancet 363:2015–2021.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Al-Kaabba AF,
    2. Al-Hamdan NA,
    3. El Tahir A,
    4. Abdalla AM,
    5. Saeed AA,
    6. Hamza MA
    (2012) Prevalence and correlates of dyslipidemia among adults in Saudi Arabia: results from a national survey. Open J Endocr Metab Dis 2:89–97.
    OpenUrl
  21. ↵
    1. Georgiadis AN,
    2. Papavasiliou EC,
    3. Lourida ES,
    4. Alamanos Y,
    5. Kostara C,
    6. Tselepis AD,
    7. et al.
    (2006) Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study. Arthritis Res Ther 8:R82.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Boers M,
    2. Nurmohamed MT,
    3. Doelman CJ,
    4. Lard LR,
    5. Verhoeven AC,
    6. Voskuyl AE,
    7. et al.
    (2003) Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 62:842–845.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Chung CP,
    2. Giles JT,
    3. Petri M,
    4. Szklo M,
    5. Post W,
    6. Blumenthal RS,
    7. et al.
    (2012) Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis. Semin Arthritis Rheum 41:535–544.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Sheng X,
    2. Murphy MJ,
    3. Macdonald TM,
    4. Wei L
    (2012) Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis. J Rheumatol 39:32–40.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Kent PD,
    2. Luthra HS,
    3. Michet C Jr.
    (2004) Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis. J Rheumatol 31:1727–1731.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Park YJ,
    2. Cho CS,
    3. Emery P,
    4. Kim WU
    (2013) LDL cholesterolemia as a novel risk factor for radiographic progression of rheumatoid arthritis: a single-center prospective study. PLoS One 8:e68975.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Dursunoğlu D,
    2. Evrengül H,
    3. Polat B,
    4. Tanriverdi H,
    5. Cobankara V,
    6. Kaftan A,
    7. et al.
    (2005) Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 25:241–245.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Kay J,
    2. Morgacheva O,
    3. Messing SP,
    4. Kremer JM,
    5. Greenberg JD,
    6. Reed GW,
    7. et al.
    (2014) Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther 16:R40.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Libby P,
    2. Ridker PM
    (2004) Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 116(Suppl 6A):9S–16S.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Maradit-Kremers H,
    2. Nicola PJ,
    3. Crowson CS,
    4. Ballman KV,
    5. Gabriel SE
    (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52:722–732.
    OpenUrlCrossRefPubMedWeb of Science
    1. Ku IA,
    2. Imboden JB,
    3. Hsue PY,
    4. Ganz P
    (2009) Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis. Circ J 73:977–985.
    OpenUrlCrossRefPubMedWeb of Science
    1. Yoo WH
    (2004) Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. J Rheumatol 31:1746–1753.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Gasparyan AY,
    2. Stavropoulos-Kalinoglou A,
    3. Mikhailidis DP,
    4. Toms TE,
    5. Douglas KM,
    6. Kitas GD
    The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol 201.
  34. ↵
    1. Sarmiento-Monroy JC,
    2. Amaya-Amaya J,
    3. Espinosa-Serna JS,
    4. Herrera-Diaz C,
    5. Anaya JM,
    6. Rojas-Villarraga A
    (2012) Cardiovascular diseases in rheumatoid arthritis : a systematic literature review in Latin Americans. Arthritis 2012, 371909.
  35. ↵
    1. Solomon DH,
    2. Kremer J,
    3. Curtis JR,
    4. Hochberg MC,
    5. Reed G,
    6. Tsao P,
    7. et al.
    (2010) Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 69:1920–1925.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Mosca L,
    2. Benjamin EJ,
    3. Berra K,
    4. Bezanson JL,
    5. Dolor RJ,
    6. Lloyd-Jones DM,
    7. et al.
    (2011) Effectiveness based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. J Am Coll Cardiol 57:1404–1423.
    OpenUrlFREE Full Text
  37. ↵
    1. Genest J,
    2. McPherson R,
    3. Frohlich J,
    4. Anderson T,
    5. Campbell N,
    6. Carpentier A,
    7. et al.
    (2009) 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult--2009 recommendations. Can J Cardiol 25:567–579.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section